Drug intelligence / Profile preview

adavosertib + docetaxel

Development stage: Unknown
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

Adavosertib (AZD1775) + docetaxel is a combination therapy consisting of a WEE1 tyrosine kinase inhibitor and a taxane chemotherapy agent. Adavosertib regulates G2-M transition and maintains genomic stability, particularly in p53-deficient tumors which require DNA repair after genotoxic therapy. This combination exploits synthetic lethality in cancer cells, with adavosertib causing premature mitotic entry and genomic instability while docetaxel disrupts microtubule function. The combination has shown promising antitumor efficacy in clinical trials, particularly for head and neck squamous cell carcinoma (HNSCC).

Other names: Wee1 inhibitor + docetaxel

Targets

TUBB (Tubulin (alpha and beta subunits))WEE1 (WEE1 G2 checkpoint kinase)

Beyond the preview

Go deeper on adavosertib + docetaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on adavosertib + docetaxel.

Explore the full profile